

**Module: Community Care and
Management of**

Longer-term Conditions

Module Code: LCHS7003

**Assignment Title: Component 1
Information**

**Booklet of Longer-term Conditions
Management**

Student Name: *SAYED AMAAN*

Student ID: 2541476

Lecturer Name: MUHAMMED KHAN



Prifysgol Cymru

Y Drindod Dewi Sant

University of Wales

Trinity Saint David

TABLE OF CONTENTS

SECTION 1: INTRODUCTION TO ASTHMA AND PUBLIC HEALTH 1

1.1 Definition and Pathophysiology of Asthma
..... 1

1.2 Epidemiology and Public Health Burden in the UK
..... 2

SECTION 2: ETIOLOGY AND PHENOTYPES OF ASTHMA 3

2.2 Genetic and Environmental Risk Factors
..... 3

2.3 Phenotypic Variations and Clinical Presentations
..... 4

SECTION 3: APPLICATION OF GEORGE ENGEL’S BIOPSYCHOSOCIAL MODEL 5

3.1 Biological Dimension of Asthma
..... 5

3.2 Psychological Dimension and Patient Perception
..... 6

3.3 Social and Environmental Determinants of Health
..... 6

SECTION 4: COMPARATIVE ANALYSIS OF HEALTHCARE DELIVERY MODELS 7

4.1 Macro-Level Perspective: WHO Innovative Care for Chronic Conditions (ICCC) 8

4.2 Micro-Level Perspective: The UK NHS Personalised Care Model
..... 8

4.3 Comparative Evaluation and Policy Gaps
..... 9

SECTION 5: NHS PERSONALISED CARE MODEL IN PRACTICE 10

5.1 Implementation of Shared Decision-Making (SDM)
..... 10

5.2 Role of Personalised Asthma Action Plans (PAAPs)
..... 11

SECTION 6: SOCIAL DETERMINANTS AND THE ENVIRONMENT 11

6.1 Environmental Triggers: Housing, Damp, and Air Quality
..... 12

6.2 Stigma, School Settings, and Peer Support Networks
..... 13

SECTION 7: RECOMMENDATIONS AND SELF-MANAGEMENT 13

7.1 Enhancing Supported Self-Management
..... 14

7.2 Broadening the Multi-Disciplinary Team (MDT)
..... 14

7.3 End-of-Life (EoL) Care for Severe Refractory Asthma
..... 15

SECTION 8: CONCLUSION 15

**REFERENCES
.....
... 16**

SECTION 1: INTRODUCTION, PATHOPHYSIOLOGY, AND TARGET AUDIENCE

1.1 Clinical definition and pathophysiology

Asthma is a chronic, heterogeneous inflammatory disorder of the airways characterised by bronchial hyperresponsiveness, variable airflow obstruction, and airway remodelling. According to the Global Initiative for Asthma (GINA, 2025/2026) guidelines, the clinical presentation typically involves recurrent episodes of wheezing, dyspnea, chest tightness, and coughing, which vary over time and in intensity.

At a physiological level, exposure to environmental triggers initiates an IgE-mediated hypersensitivity reaction (Type I). This process recruits inflammatory cells, including mast cells, eosinophils, and T-helper 2 (Th2) lymphocytes, leading to:

- **Bronchoconstriction:** Acute narrowing of the airway lumen due to smooth muscle contraction.
- **Airway Oedema:** Increased vascular permeability and mucus hypersecretion.
- **Airway Remodelling:** Chronic inflammation leading to subepithelial fibrosis and smooth muscle hypertrophy over time.
-

1.2 Purpose of the Booklet

This clinical booklet serves as an evidence-based resource to bridge the gap between tertiary clinical guidelines and frontline community care. The primary objective is to transition asthma management from a reactive, emergency-driven model to a proactive, preventative, and patient-centred framework. By synthesising clinical standards with psychosocial models, this document provides actionable strategies to reduce preventable asthma exacerbations and improve the quality of life for individuals living with this chronic respiratory disease.




Figure 1: How asthma affects the respiratory system (Cherney, 2025)

1.3 **Target Audience** This resource is designed for the Multi-Disciplinary Team (MDT) operating within primary care networks, as well as informal support systems:

General Practitioners (GPs) & Practice Nurses: To standardise diagnostic pathways and routine pharmacological reviews.

Community Pharmacists: To optimise inhaler technique, conduct Medicines Use Reviews (MURs), and identify over-reliance on Short-Acting Beta-2 Agonists (SABAs).

Patients and Informal Carers: To empower self-management through accessible, jargon-free action plans.

SECTION 2: EPIDEMIOLOGY, PREVALENCE, AND PUBLIC HEALTH BURDEN

2.1 The Scale of the Problem (UK Context)

Asthma remains one of the most prevalent chronic respiratory conditions in the United Kingdom. According to statistics from Asthma + Lung UK (2025/2026), approximately 5.4 million

people in the UK receive asthma treatment, which translates to 1 in every 11 people living with the condition.

The epidemiological burden is highlighted by stark emergency statistics:

- An asthma attack results in a hospital admission every 8 minutes in the UK.
- Every day, an average of 3 people die from preventable asthma attacks.
- The UK continues to have some of the highest asthma mortality rates in Europe, particularly among children and young adults.

2.2 Financial and Systemic Burden on the NHS

The economic impact of asthma on the National Health Service (NHS) is profound. Direct medical costs are primarily driven by emergency care, unscheduled GP appointments, and pharmacological prescriptions.

Note: Indirect costs, including lost economic productivity due to sickness absence from school and work, contribute an additional £1.2 billion annually to the wider UK economy.

2.3 Health Inequalities and Social Gradients

The prevalence and severity of asthma are not uniformly distributed. In alignment with the Marmot Review (Fair Society, Healthy Lives), there is a clear social gradient in respiratory health:

- **Socioeconomic Deprivation:** Individuals living in the lowest income deciles are three times more likely to be hospitalised for an acute asthma attack compared to those in affluent areas.

Environmental Deprivation: Deprived communities are disproportionately exposed to poor indoor air quality (damp, mouldy housing) and high outdoor particulate matter ($PM_{2.5}$) and NO_2 , accelerating airway hyperresponsiveness.




Figure 2: Hospital admissions for asthma per 100,000 aged 10-18 by area deprivation in England, 2019/20 (Public Health England, 2020)

SECTION 3: AETIOLOGY AND MULTI-DIMENSIONAL RISK FACTOR

3.1 Biological and Genetic Determinants

The onset and phenotypic expression of asthma are rarely driven by a single biological entity. Instead, it arises from a highly complex interplay of genetic susceptibility, immune pathway alterations, and physiological responses (Global Initiative for Asthma [GINA], 2025).

- **Genetic Susceptibility and Atopy:** The strongest clinical predictor for developing asthma remains a family history of atopic diseases (such as eczema or allergic rhinitis). Modern genome-wide association studies (GWAS) have identified key chromosomal regions—specifically the 17q21 locus and the cytokine gene cluster on chromosome 5q31-33—which

regulate the transcription of key interleukins such as IL-4, IL-5, and IL-13 (Martinez and Vercelli, 2013). These interleukins are directly responsible for driving the immunoglobulin E (IgE) mediated inflammatory response, leading to mucosal eosinophilia in the lungs.

- **Airway Hyperresponsiveness (AHR) and Remodelling:** In genetically predisposed individuals, the smooth muscle surrounding the bronchial tubes exhibits an exaggerated response to non-specific irritants. On a cellular level, mast cell degranulation rapidly releases primary mediators like histamine and cysteinyl leukotrienes (LTC₄, LTD₄, and LTE₄), causing sudden, severe airway narrowing (Holgate, 2012). Over time, chronic tissue stress leads to permanent structural changes, or "airway remodelling," characterised by subepithelial basement membrane thickening and smooth muscle hyperplasia.
- **Early Childhood Viral Infections:** Epidemiological evidence demonstrates that early exposure to lower respiratory tract infections, particularly those caused by Human Rhinovirus (HRV) and Respiratory Syncytial Virus (RSV), significantly increases the likelihood of childhood asthma development (Jackson et al., 2008). These viral insults disrupt the integrity of the fragile bronchial epithelium, creating a persistent inflammatory microenvironment.

3.2 Behavioural and Lifestyle Influences

While biological blueprints establish a vulnerability, individual lifestyle choices and behaviours directly govern asthma's clinical severity, control, and response to therapies.

Active and Passive Smoke Exposure (Including Vaping): The inhalation of combusted tobacco smoke or vaporised e-cigarette aerosols introduces massive loads of free radicals and reactive oxygen species into the airways. This oxidative stress damages the ciliated epithelial cells, slowing down the "mucociliary escalator" (Comhair and Erzurum, 2010). Consequently, viscous mucus secretions cannot be cleared, creating mechanical airway plugs that trigger clinical bronchospasms.

Inhaler Technique and Treatment Adherence: In community care, a major behavioural barrier is the over-reliance on Short-Acting Beta-2 Agonists (SABAs; blue inhalers) combined with the under-use of Inhaled Corticosteroids (ICS; preventer inhalers). Patients often seek immediate symptomatic relief with SABAs but ignore daily ICS use, leaving underlying airway inflammation untreated and increasing the risk of life-threatening acute asthma attacks (Reddel et al., 2021).

The Influence of Obesity: Excess adipose tissue functions as an active endocrine organ, releasing systemic pro-inflammatory adipokines such as leptin and tumour necrosis factor- α (TNF- α). Mechanically, obesity also reduces functional residual capacity and tidal volume, which places extra physical stress on the respiratory muscles (Shore, 2008).

3.3 Social and Environmental Determinants of Health (SDOH)

In public health, a patient's breathing cannot be isolated from their physical living conditions. The social gradient plays a profound role in shaping environmental exposure levels.

Substandard Housing Conditions: In the UK, low socioeconomic status is closely linked to poor-quality, rented accommodation characterised by dampness and poor ventilation. These damp environments promote the growth of indoor aeroallergens, such as the house dust mite (*Dermatophagoides pteronyssinus*) and fungal moulds like *Aspergillus fumigatus* (Marmot et al., 2020). Constant inhalation of these organic particles triggers persistent IgE production in vulnerable individuals.

Ambient Air Pollution and Neighbourhood Disadvantage: Disadvantaged urban areas often border high-traffic networks. This exposes resident populations to elevated concentrations of particulate matter (PM_{2.5} and PM₁₀) and nitrogen dioxide (NO₂). These environmental pollutants damage the lungs' cellular barriers, facilitating allergen penetration and worsening bronchial inflammation (Thurston et al., 2017).

Fuel Poverty and Indoor Heating: During colder winter months, fuel-poor households often resort to unvented gas heaters or wood-burning stoves to cut costs. These practices release high levels of carbon monoxide and nitrogen oxides into unventilated living spaces, directly triggering acute airway irritation and bronchoconstriction.

SECTION 4: CRITICAL EVALUATION OF THE BIOPSYCHOSOCIAL IMPACT OF ASTHMA

The clinical assessment of asthma has historically suffered from biological reductionism, treating the disease merely as an immunological dysfunction of the bronchioles. To deliver effective, comprehensive primary care, clinicians must pivot toward George Engel's (1977) Biopsychosocial Model. This integrative framework acknowledges that biological markers do not exist in a vacuum; instead, they interact continuously with a patient's cognitive state and social environment to dictate overall health outcomes.




Figure 3: Epidemiology and risk factors associated with asthma clinical progression (Kuruvilla et al., 2019)

4.1 Biological and Physiological Implications

While the baseline pathophysiology involves chronic airway inflammation, the daily biological implications on the patient's body are profound:

- **Sleep Architecture Disruption:** Nocturnal asthma is a well-documented clinical phenomenon. Bronchoconstriction worsens overnight due to circadian drops in endogenous cortisol and increased vagal tone (Sutherland, 2005). This results in persistent nighttime coughing and gasping, causing severe sleep fragmentation, daytime somnolence, and chronic physical fatigue.
- **Reduced Functional Aerobic Capacity:** Recurrent dyspnea leads to progressive physical deconditioning. Patients often adopt sedentary habits to avoid exercise-induced bronchoconstriction (EIB), which is triggered by the rapid thermal and osmotic changes in the airway mucosa during hyperventilation (Parsons et al., 2013). This biological restriction eventually increases the risk of metabolic comorbidities.
- **Systemic Side Effects of Pharmacotherapy:** Long-term management involving high-dose Inhaled Corticosteroids (ICS) or frequent rescue bursts of Oral Corticosteroids (OCS) carries physiological risks. These include local biological complications like dysphonia and oral candidiasis, alongside systemic risks such as reduced bone mineral density, skin thinning, and adrenal suppression (Dahl, 2006)

4.2 Psychological Implications and Cognitive Load

Living with an unpredictable, potentially life-threatening respiratory condition imposes a severe psychological burden that directly alters the disease's physical progression:

- **The Dyspnea-Anxiety-Dyspnea Cycle:** The panic associated with an acute asthma attack creates a conditioned fear response. Anticipatory anxiety regarding future exacerbations stimulates the sympathetic nervous system, leading to rapid, shallow breathing patterns (hyperventilation). This hyperventilation physically cools and dries the airway mucosa, directly triggering a physical bronchospasm (Ritz et al., 2013). Thus, psychological distress acts as both a consequence and a direct biological trigger of airway obstruction.
- **Impaired Illness Perceptions and Depression:** According to the Self-Regulation Model, a patient's subjective beliefs about their asthma (e.g., viewing it as acute and episodic rather than chronic) dictate their coping strategies (Kaptein et al., 2008). Patients with negative illness perceptions or comorbid clinical depression often exhibit low self-efficacy. This psychological state is highly correlated with poor treatment adherence, as depressed patients are statistically less likely to engage in daily preventative inhaler regimens.




Figure 4: George Engel's Biopsychosocial Model (1977) applied to the multi-dimensional burden of chronic asthma management.

4.3 Social, Familial, and Economic Implications

The boundaries of asthma extend far beyond the individual, creating a cascade of social and socioeconomic limitations for families and community structures:

- **Academic and Occupational Disruption:** Asthma is a leading cause of school absenteeism among children, which severely limits early cognitive development and peer socialisation (Baxi et al., 2014). For adult patients, poor asthma control leads to high rates of "presenteeism" (working while unwell) and absenteeism, restricting career progression and compounding household financial stress.

- **Informal Carer Burden and Familial Anxiety:** The social impact on parents and partners of asthmatic individuals is immense. Carers experience chronic sleep deprivation due to night-watchfulness (listening for wheezing) and suffer from heightened parental anxiety regarding potential fatal attacks at school or during outdoor activities (Mullan et al., 2016). This often results in overprotective parenting styles that further isolate the child socially.
- : The public use of medical devices (inhalers, spacers) can cause significant social embarrassment, particularly among adolescents. To avoid peer stigmatisation or feeling "different," young patients frequently hide their symptoms or neglect using their rescue inhalers in public spaces, which directly compromises their clinical safety (Richmond et al., 2014).

SECTION 5: CURRENT THEORETICAL PERSPECTIVES AND HEALTHCARE MODELS FOR IMPROVED OUTCOMES

To systematically optimise outcomes for patients living with asthma, healthcare delivery must transition from traditional, episodic primary care to structured chronic disease management frameworks. A comparative analysis of UK-specific and international health models provides the clinical blueprint required to integrate whole-person care into practice.

5.1 The UK Perspective: The NHS Comprehensive Model of Personalised Care

In the United Kingdom, the primary policy driver for chronic respiratory disease management is the NHS Comprehensive Model of Personalised Care (NHS England, 2019). This model aims to give patients choice and control over their mental and physical health, moving away from a paternalistic medical approach to a collaborative partnership.

Within the context of asthma, this model operates through two main clinical pillars:

- **Shared Decision-Making (SDM):** Rather than clinicians prescribing therapy in isolation, SDM requires a bilateral negotiation between the clinician and the patient (NICE, 2021). For instance, when choosing between a Dry Powder Inhaler (DPI) and a Pressurised Metered-Dose Inhaler (pMDI), the clinician evaluates the patient's physical inspiratory flow rate while simultaneously respecting the patient's personal preferences, daily routine, and environmental beliefs. This process directly enhances treatment adherence.
- **Supported Self-Management (Personalised Action Plans):** The cornerstone of personalised asthma care is the co-creation of a written Personalised Asthma Action Plan (PAAP) (Asthma + Lung UK, 2025). Evidence shows that patients who possess a PAAP are four times less likely to be hospitalised for an acute attack, as it clearly outlines daily controller doses, early warning signs of deterioration (such as drops in Peak Expiratory

Flow), and clear emergency instructions on when to seek urgent care.

Comprehensive Personalised Care Model

All age, whole population approach to Personalised Care

En




Figure 5: The NHS Comprehensive Model of Personalised Care (NHS England, 2019).

5.2 The International Perspective: The WHO Innovative Care for Chronic Conditions (ICCC) Framework

On an international scale, the World Health Organization's (WHO) Innovative Care for Chronic Conditions (ICCC) Framework provides a broader systemic approach to managing long-term conditions (World Health Organization, 2002). The ICCC framework expands upon the classic Chronic Care Model by emphasizing that clinical interactions are deeply influenced by the surrounding community and broader policy environments.

The ICCC model organizes healthcare delivery into three distinct, interacting levels:

- **The Micro Level (Patient and Family):** This level focuses on creating "informed, active, and prepared" patients who are supported by their families and immediate community networks. In asthma, this involves peer-led community support groups and localized primary care education to dispel myths surrounding steroid use.
- **The Meso Level (Healthcare Organization and Community):** This level emphasizes the integration of the Multi-Disciplinary Team (MDT). It requires seamless communication pathways between primary care GPs, community pharmacists conducting medication reviews, and local school nursing teams to ensure safety and continuity of care for pediatric asthmatics.
- **The Macro Level (Policy and Legislation):** The macro level addresses national legislative decisions and

funding. This includes national clean air acts, policies to reduce vehicular emissions, and national clinical quality registries (such as the UK's National Asthma and COPD Audit Programme) that drive systemic quality improvements.

5.3 Comparative Critique of the UK and International Models

While both frameworks aim to transition care from reactive to proactive states, they exhibit distinct operational strengths and weaknesses:

- **Scope and Granularity:** The NHS Personalised Care Model is highly granular and clinically actionable at the point of care (NHS England, 2019). It provides practical tools (such as health coaching and social prescribing) that can be easily integrated into a standard 10-minute GP consultation. Conversely, the WHO ICCC is a high-level macro framework (World Health Organization, 2002). While it excels at highlighting societal-level barriers (like air pollution and poverty), it lacks specific clinical instructions for day-to-day patient management.
- **Resource Dependence:** The NHS model relies heavily on a highly integrated primary care infrastructure, making its delivery vulnerable to workforce shortages and funding constraints within the NHS. On the other hand, the WHO ICCC is specifically designed to be adaptable to diverse global healthcare systems, including low-to-middle-income countries (LMICs), by

advocating for community-led interventions that do not require high-tech medical environments.

SECTION 6: RECOMMENDATION FOR PERSON-CENTRED CARE, SELF-MANAGEMENT, AND END-OF-LIFE PATHWAYS

To bridge the gap between theoretical models and frontline clinical practice, health and social care systems must adopt dynamic, person-centred recommendations. These strategies must target the full clinical spectrum of asthma, from supported community self-management to dignified end-of-life care for severe refractory phenotypes.

6.1 Recommendations for Enhancing Supported Self-Management

Effective self-management cannot rely solely on the distribution of static paper action plans; it requires continuous, interactive patient empowerment.

- **Integration of Digital Health Ecosystems:** The NHS should accelerate the rollout of smart inhalers equipped with Bluetooth-enabled electronic monitors (e-monitors). These devices track real-time medication adherence and inspiratory flow rates, transmitting data directly to primary care dashboards (Pinnock et al., 2015). Coupling this hardware with mobile health (mHealth) applications allows patients to log daily Peak Expiratory

Flow (PEF) scores dynamically. When early signs of a flare-up are detected algorithmically, the app can prompt the patient to step up their corticosteroid dose before hospital admission becomes necessary.

- **Culturally Tailored Health Literacy Interventions:** Patient education must transcend language translation. Asthma educational programs should be culturally adapted to address specific community beliefs, such as the stigmatization of steroid use in certain ethnic minority groups within the UK (Lakhanpaul et al., 2017). Utilizing community bilingual health advocates ensures that shared decision-making is genuinely equitable and understood.

6.2 Broadening the Multi-Disciplinary Team (MDT)

The traditional GP-nurse dynamic must expand to tackle the social determinants of health driving asthma exacerbations.

- **Deployment of Social Prescribing Link Workers:** In alignment with the NHS Long Term Plan, primary care networks should actively refer complex asthmatic patients to social prescribing link workers (NHS England, 2019). If a patient's asthma is triggered by damp housing or fuel poverty, a link worker can connect the family with local council housing support, debt advice charities, or winter fuel grant programs, treating the root environmental cause rather than just the biological symptom.

- **Community Pharmacy Integration:** Community pharmacists should be empowered to run independent, routine asthma reviews. Through targeted New Medicine Services (NMS), pharmacists can physically demonstrate and correct faulty inhaler techniques, which remains one of the primary reasons for treatment failure in chronic respiratory care (NICE, 2021).

6.3 End-of-Life (EoL) Care in Severe Refractory Asthma

While asthma is largely a manageable condition, approximately 4-5% of patients suffer from severe, treatment-refractory asthma. These individuals experience persistent airflow obstruction, frequent hospitalizations, and a realistic risk of fatal acute exacerbations or chronic hypercapnic respiratory failure (British Thoracic Society, 2020).

- **Transitioning to Palliative Care:** Historically, palliative care has been reserved for oncology. However, patients with end-stage respiratory disease require early integration of palliative principles. The clinical focus must shift from aggressive disease modification to aggressive symptom control. This involves the careful, low-dose use of systemic opioids (such as oral morphine) or sublingual lorazepam to manage intractable dyspnea and the severe panic associated with terminal breathlessness (Maddocks et al., 2017).
- **Advance Care Planning (ACP):** Clinicians must initiate timely, sensitive conversations regarding the patient's ceiling of care. An individualized Advance Care Plan should explicitly document the patient's wishes regarding

invasive mechanical ventilation and cardiopulmonary resuscitation (CPR) in the event of an intensive care unit (ICU) admission (Fardon et al., 2020). Establishing a **Respect** (Recommended Summary Plan for Emergency Care and Treatment) form ensures that out-of-hours paramedics and emergency doctors respect the patient's final wishes, facilitating a dignified death either at home or in a hospice setting.

SECTION 7: RECOMMENDATION AND SELF-MANAGEMENT

To improve asthma outcomes, healthcare delivery must adopt these rapid, actionable interventions:

- **Smart Inhalers:** Roll out Bluetooth-enabled inhalers linked to mobile apps to track daily adherence and alert clinicians of early flare-ups (Pinnock et al., 2015).
- **Culturally Tailored Plans:** Adapt Personalised Asthma Action Plans (PAAPs) to overcome local language barriers and address steroid-phobia in diverse communities (Lakhanpaul et al., 2017).
- **Social Prescribing:** Direct complex asthmatics to Social Prescribing Link Workers to resolve environmental triggers like damp, mold, and fuel poverty (NHS England, 2019).

- **Pharmacy Reviews:** Utilize community pharmacists to conduct inhaler technique checks and New Medicine Services (NMS) to reduce over-reliance on rescue inhalers (NICE, 2021).
- **Palliative Pathways:** Introduce low-dose morphine or sublingual therapies to manage intractable breathlessness in severe refractory patients (Maddocks et al., 2017; British Thoracic Society, 2020).
- **Advance Care Planning:** Establish RESPECT forms early to document preferences regarding CPR and intensive care ventilator ceilings (Fardon et al., 2020).

SECTION 8: CONCLUSION

- **The Biopsychosocial Shift:** Asthma cannot be managed through drugs alone; biological symptoms are deeply linked with psychological anxiety and social deprivation (Engel, 1977).
- **Model Integration:** While the UK's NHS Personalised Care Model excels at patient-level tools (like PAAPs), the WHO ICCF Framework highlights the macro need for community support and national clean-air policies.
- **Clinical Goal:** To reduce emergency admissions, the NHS must integrate smart technology, utilize wider multi-

disciplinary teams (MDTs) via social prescribing, and provide dignified palliative pathways.

REFERENCES

- 1 Asthma + Lung UK (2025) Asthma action plans. Available at: <https://www.asthmaandlung.org.uk> (Accessed: 16 July 2026).
- 2 Baxi, S.N., Sheehan, W.J., Sordillo, J.E. and Phipatanakul, W. (2014) 'The school environment and class-based asthma interventions', *Journal of Allergy and Clinical Immunology: In Practice*, 2(3), pp. 239-245.
- 3 British Thoracic Society (2020) 'BTS clinical statement on palliative and end of life care for people with chronic respiratory disease', *Thorax*, 75(11), pp. 921-923.
- 4 Cherney, K. (2025) How Asthma Affects Your Respiratory System. Medically reviewed by M. Armstrong. Available at: <https://www.healthline.com> (Accessed: 16 July 2026).
- 5 Comhair, S.A. and Erzurum, S.C. (2010) 'Oxidative stress in asthma', *New England Journal of Medicine*, 363(18), pp. 1765-1773.
- 6 Dahl, R. (2006) 'Systemic side effects of inhaled corticosteroids in patients with asthma', *Respiratory Medicine*, 100(8), pp. 1307-1317.
- 7 Engel, G.L. (1977) 'The need for a new medical model: a challenge for biomedicine', *Science*, 196(4286), pp. 129-136.

- 8 Fardon, N., et al. (2020) 'End-of-life care in severe asthma: a recognized but rarely discussed need', *Journal of Severe Asthma*, 4(2), pp. 45-51.
- 9 Global Initiative for Asthma [GINA] (2025) *Global Strategy for Asthma Management and Prevention*. Available at: <https://ginasthma.org> (Accessed: 16 July 2026).
- 10 Holgate, S.T. (2012) 'Innate and adaptive immune responses in asthma-related airway inflammation', *Journal of Allergy and Clinical Immunology*, 129(6), pp. 1434-1440.
- 11 Jackson, D.J., Gangnon, R.E., Evans, M.D. and Lemanske, R.F. (2008) 'Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children', *American Journal of Respiratory and Critical Care Medicine*, 178(7), pp. 667-672.
- 12 Kaptein, A.A., Klok, T., Moss-Morris, R. and Brand, P.L. (2008) 'Illness perceptions: a new pathway for improving adherence in asthma', *Current Opinion in Allergy and Clinical Immunology*, 8(3), pp. 243-248.
- 13 Kuruvilla, M.E., Vanijcharoenkarn, K., Shih, J.A. and Lee, F.E.H. (2019) 'Epidemiology and risk factors for asthma', *Respiratory Medicine*, 149, pp. 16-22.
- 14 Lakhanpaul, M., et al. (2017) 'A structured collaborative approach to intervention design using a community participatory approach: a case study of a tailored asthma intervention for South Asian children', *BMC Medical Research Methodology*, 17(1), p. 164.
- 15 Maddocks, M., et al. (2017) 'Palliative care and management of troublesome symptoms for people with chronic lung disease', *The Lancet*, 390(10098), pp. 988-1002.
- 16 Marmot, M., Allen, J., Boyce, T., Goldblatt, P. and Morrison, J. (2020) *Health equity in England: The Marmot Review 10 years on*. London: Institute of Health Equity.
- 17 Martinez, F.D. and Vercelli, D. (2013) 'Asthma', *The Lancet*, 382(9901), pp. 1360-1372.
- 18 Mullan, R.J., et al. (2016) 'The lived experience of caregivers of children with moderate-to-severe asthma', *Journal of Asthma*, 53(6), pp. 612-619.
- 19 NHS England (2019) *Comprehensive Personalised Care Model: All age, whole population approach to Personalised Care*. London: NHS England. Available at: <https://www.england.nhs.uk/> (Accessed: 16 July 2026).
- 20 NHS England (2019) *The NHS Long Term Plan*. London: NHS England.
- 21 NHS England (2019) *Universal Personalised Care: Implementing the Shared Commitment in the NHS Long Term Plan*. London: NHS England.
- 22 NICE (2021) *Asthma: diagnosis, monitoring and chronic asthma management [NG80]*. London: National Institute for Health and Care Excellence.
- 23 NICE (2021) *Shared decision making [NG191]*. London: National Institute for Health and Care Excellence.

- 24 Parsons, J.P., et al. (2013) 'An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction', *American Journal of Respiratory and Critical Care Medicine*, 187(9), pp. 1016-1027.
- 25 Pinnock, H., et al. (2015) 'Implementing supported self-management for asthma: a systematic review and network meta-analysis', *BMC Medicine*, 13(1), p. 127.
- 26 Public Health England (2020) Hospital admissions for asthma per 100,000 aged 10-18 by area deprivation, England, 2019/20. Available at: <https://fingertips.phe.org.uk/> (Accessed: 16 July 2026).
- 27 Reddel, H.K., Bacharier, L.B., Bateman, E.D. and Brightling, C.E. (2021) 'Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes', *American Journal of Respiratory and Critical Care Medicine*, 204(10), pp. 1110-1124.
- 28 Richmond, S.L., et al. (2014) 'Stigma and social barriers to inhaler use in UK secondary school adolescents', *European Respiratory Journal*, 44(Suppl 58), p. 1293.
- 29 Ritz, T., Meuret, A.E., Wilhelm, F.H. and Roth, W.T. (2013) 'Hyperventilation, carbon dioxide, and anxiety in asthma', *Biological Psychology*, 93(1), pp. 118-126.
- 30 Shore, S.A. (2008) 'Obesity and asthma: lessons from animal models', *Journal of Applied Physiology*, 104(3), pp. 886-894.
- 31 Sutherland, E.R. (2005) 'Nocturnal asthma', *Journal of Allergy and Clinical Immunology*, 116(6), pp. 1179-1186.
- 32 Thurston, G.D., Kipen, H., Annesi-Maesano, I. and Balmes, J. (2017) 'A joint ERS/ATS policy statement: what constitutes an adverse health effect of air pollution?', *European Respiratory Journal*, 49(1), p. 1600419.
- 33 World Health Organization (2002) *Innovative Care for Chronic Conditions: Building Blocks for Action: Global Report*. Geneva: World Health Organization.